For instance, combination treatment with the SMOi saridegib and the EGFR inhibitor cetuximab abrogates tumor growth and delays tumor recurrence in mouse xenograft models derived from metastatic head and neck squamous cell carcinoma (Bowles et al., 2016). This evidence concerns the gene EGFR and neoplasm.